Sunday, 24 March 2019

Dr Reddy launches cholesterol-lowering medicine in US market

10 October 2018 | News

The Colesevelam HCI tablet is a generic version of Japanaese pharmaceutical company Daiichi Sankyo's Welchol

Dr Reddy’s Laboratories Ltd. has announced the launch of a cholesterol-lowering medication Colesevelam HCl Tablets in the United States market approved by the US Food and Drug Administration (USFDA).

The Colesevelam HCI tablet is a generic version of Japanese pharmaceutical company Daiichi Sankyo's Welchol.

The WELCHOL brand and generic had an US sale of approximately $ 471 million for the most recent twelve months ending in August 2018 according to IMS Health.

The tablets will be available in 625 mg with 180-count bottle size, Dr Reddy's said in a statement.

After the launching Shares of Dr Reddy's Laboratories climbed about 1 percent in early trade. Shares of the company hit an intraday high of Rs 2,600 on BSE, up as much as 6.3 percent.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Can collaboration between startups and big life sciences companies offer a disruptive breakthrough?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls